Abstracts tagged "Histone Modification and epigenetics"

Abstract Number: 204 • 2015 ACR/ARHP Annual Meeting
Histone Methylation Profiling in Peripheral White Blood Cells As a Candidate Biomarker for Behcet’s Disease
Yoshimi Aizaki^1,2, Yasuto Araki^1,2, Kojiro Sato¹, Yuji Akiyama¹ and Toshihide Mimura^1,2, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Project Research Division, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Behcet’s disease (BD) is a chronic recurrent, multisystem inflammatory disorder. The phenotypic characteristics include oral aphtha, genital ulcers, uveitis and skin lesions. No specific…
Abstract Number: 1836 • 2013 ACR/ARHP Annual Meeting
Suppression Of HDAC5 Expression By Inflammatory Cytokines Is Required To Promote CXCL Chemokine Production In RA FLS
Chiara Angiolilli¹, A.M. Grabiec¹, P.A. Kabala¹, Paul-Peter Tak², Dominique L. Baeten³ and Kris A. Reedquist⁴, ¹Department of Experimental Immunology, Department of Clinical Immunology and Rheumatology Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Academic Medical Center / currently also GlaxoSmithKline, Amsterdam, Netherlands, ³Department of Clinical Immunology and Rheumatology Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁴Department of Experimental Immunology and Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Histone deacetylases (HDACs) are important regulators of gene expression and protein function in the immune system. HDAC inhibitors (HDACi) display anti-inflammatory properties in animal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].